Adverum Biotechnologies Inc logo

ADVM - Adverum Biotechnologies Inc News Story

$12.38 -0.5  -3.5%

Last Trade - 18/09/20

Sector
Healthcare
Size
Mid Cap
Market Cap £912.0m
Enterprise Value £695.1m
Revenue £194k
Position in Universe 2253rd / 6396

BRIEF-Adverum Biotech Announces New Mid-Stage Trial For ADVM-022 In Diabetic Macular Edema

Thu 28th May, 2020 10:05pm
May 28 (Reuters) - Adverum Biotechnologies Inc  ADVM.O :
    * ADVERUM BIOTECHNOLOGIES ANNOUNCES NEW INFINITY PHASE 2
TRIAL FOR
ADVM-022 IN DIABETIC MACULAR EDEMA, REPORTS RECENT BUSINESS
PROGRESS AND FIRST QUARTER 2020 FINANCIAL RESULTS
    * Q1 LOSS PER SHARE $0.31
    * Q1 EARNINGS PER SHARE ESTIMATE $-0.27 -- REFINITIV IBES
DATA
    * INFINITY TRIAL INITIATED FOR PATIENTS WITH DIABETIC
MACULAR
EDEMA

Source text for Eikon:  ID:nGNX8jqtZl 
Further company coverage:  ADVM.O 

 ((Reuters.Briefs@thomsonreuters.com;))
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.